Hormonal
Switching antipsychotics to Aripiprazole results in significant weight reduction, but adding Aripiprazole to an existing regimen is not recommended due to increased risks of agitation and akathisia.
If you are gaining weight on your current antipsychotic, switching to Aripiprazole can lead to significant weight loss. However, do not simply add Aripiprazole to your current medication, as this can cause agitation and anxiety. Switching must be done carefully with your doctor, weighing the mental health stability against the metabolic benefits.
A meta-analysis showed that switching antipsychotics to aripiprazole resulted in significant weight reduction (-5.52 kg)... Therefore, in our opinion adding aripiprazole to an existing antipsychotic regime plays no role in the treatment of AiWG.
Why this rating
Supported by meta-analyses showing weight reduction, but balanced against significant adverse event rates.
Source
Antipsychotic‐induced weight gain: Is the weight over? New guidelines needed
Nini de Boer et al. · Acta Psychiatrica Scandinavica · 2022
DOI 10.1111/acps.13485
More from this paper
- Metformin is an effective and well-tolerated adjunctive pharmacological intervention for treating and preventing antipsychotic-induced weight gain in patients with severe mental illness.Good
- Topiramate is effective for reducing antipsychotic-induced weight gain but is limited by poor tolerability, specifically cognitive difficulties and paresthesia.Good
- GLP-1 agonists (Liraglutide and Semaglutide) are promising interventions for reducing antipsychotic-induced weight gain, with Semaglutide showing superior efficacy to Liraglutide in general obesity populations, though evidence in SMI is still emerging.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →